Audio Resource #1: ZOSTER EASE: A Phase Ib Shingles Treatment Study

Wintermute Biomedical is conducting a Phase Ib clinical trial (WNTR-VZV-001) to assess the safety and tolerability of Solexan™, a topical treatment for shingles and shingles-induced pain. This double-blind, randomized, placebo-controlled study will enrol up to 30 participants with shingles who will apply Solexan™ or a placebo twice daily for 10 days. The trial's primary endpoints focus on safety, while secondary and exploratory endpoints examine pain reduction and lesion healing.

Listen to this audio clip for an overview of the study's design, objectives, expected outcomes, and potential impact in addressing the need for effective, non-invasive shingles treatments.

Note: This audio clip was generated using AI to provide a clear and engaging overview of our ZosterEase Phase Ib trial. We value your feedback—let us know what you think.